88. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines(R)) for Uterine Neoplasms V1.2018. Available at: http://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Accessed March 21, 2018.
89. Judson I., Verweij J., Gelderblom H. et al. Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol 2014; 15(4): 415 - 23.
90. Hensley M.L., Maki R., Venkatraman E. et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol 2002; 20(12): 2824 - 31.
91. Miller D.S., Blessing J.A., Lentz S.S., Waggoner S.E. A phase II trial of topotecan in patients with advanced, persistent, or recurrent endometrial carcinoma: a gynecologic oncology group study. Gynecol Oncol 2002; 87: 247 - 51.
92. Dizon D.S. Treatment options for advanced endometrial carcinoma. Gynecol Oncol 2010; 117(2): 373 - 81. DOI: 10.1016/j.ygyno.2010.02.007.
93. Escobar P.F., Markman M., Zanotti K. et al. Phase 2 trial of pegylated liposomal doxorubicin in advanced endometrial cancer. J Cancer Res Clin Oncol 2003; 129(11): 651 - 4.
94. Fracasso P.M., Blessing J.A., Molpus K.L. et al. Phase II study of oxaliplatin as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 103(2): 523 - 6.
95. Markman M., Blessing J., Rubin S.C. et al. Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 2006; 101(3): 436 - 40.
96. Homesley H.D., Meltzer N.P., Nieves L. et al. A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer. Int J Clin Oncol 2008; 13(1): 62 - 5.
97. Lissoni A., Zanetta G., Losa G. et al. Phase II study of paclitaxel as salvage treatment in advanced endometrial cancer. Ann Oncol 1996; 7(8): 861 - 3.
98. Lincoln S., Blessing J.A., Lee R.B., Rocereto T.F. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2003; 88(3): 277 - 81.
99. Marabelle A., Le D.T., Ascierto P.A. et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair-deficient cancer: results from the phase II KEYNOTE-158 Study. JCO 2020; 38(1): 1 - 10.
100. Makker V., Rasco D., Vogelzang N.J. et al. Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer; an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. Lancet 2019; 20(5): 711 - 8.
101. Sutton G.P., Blessing J.A., Homesley H.D. et al. Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. Cancer 1994; 73(5): 1453 - 5.
102. Muggia F.M., Blessing J.A., Sorosky J., Reid G.C. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: a Gynecologic Oncology Group study. J Clin Oncol 2002; 20: 2360 - 4.
103. Mouridsen H.T., Bastholt L., Somers R. et al. Adriamycin versus epirubicin in advanced soft tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer Clin Oncol 1987; 23(10): 1477 - 83.
104. Sutton G.P., Blessing J.A., Barrett R.J. et al. Phase II trial of ifosfamide and mesna in leiomyosarcoma of the uterus: a Gynecologic Oncology Group study. Am J Obstet Gynecol 1992; 166(2): 556 - 9.
105. Amant F., Coosemans A., Debiec-Rychter M. et al. Clinical management of uterine sarcomas. Lancet Oncol 2009; 10(12): 1188 - 98.
106. van der Graaf W.T., Blay J.Y., Chawla S.P. et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012; 379(9829): 1879 - 86.
107. Demetri G.D., Chawla S.P., von Mehren M. et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthra-cyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol 2009; 27(25): 4188 - 96.
108. Muggia F., Blessing J.A., Method M. Evaluation of vinorelbine in persistent or recurrent squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 2004; 92(2): 639 - 40.
109. Garcia A.A., Blessing J.A., Nolte S., Mannel R.S. A phase II evaluation of weekly docetaxel in the treatment of recurrent or persistent endometrial carcinoma: a study by the Gynecologic Oncology Group. Gynecol Oncol 2008; 111(1): 22 - 6.
110. Blay J.Y., P., Bauer S. et al. Eribulin versus dacarbazine in patients with leiomyosarcoma: subgroup analysis from a phase 3, open-label, randomised study. British J Cancer 2019; 120(11): 1026 - 32.
111. Look K.Y., Sandler A., Blessing J.A. et al. Phase II trial of gemcitabine as secondline chemotherapy of uterine leiomyosarcoma: a Gynaecologic Oncology Group (GOG) Study. Gynaecol Oncol 2004; 92: 644 - 7.
112. Урманчеева А.Ф., Ульрих Е.А. Принципы лечения сарком матки. Практическая онкология 2008; 9(3): 132 - 6.
113. Temkin S.M., Fleming G. Current treatment of metastatic endometrial cancer. Cancer Control 2009; 16(1): 38.
114. Фармакотерапия опухолей. Под ред. А.Н. Стукова, М.А. Бланка, Т.Ю. Семиглазовой, А.М. Беляева. СПб: Вопросы онкологии, 2017. 512 с.
115. Anderson S., Aghajanian C. Temozolomide in uterine leiomyosarcomas. Gynecol Oncol 2005; 98(1): 99 - 103.
116. Morgan J.A., Cesne A.L., Chawla S.M. et al. Randomized phase II study of trabectedin in patients with liposarcoma and leiomyosarcoma (Lsarcomas) after failure of prior anthracylines (A) and ifosfamide (I). J Clin Oncol 2007; 25(18S): 10060.
117. Ульрих Е.А. Особенности лечения сарком матки. Практическая онкология 2013; 14(2): 127 - 34.
118. Jhingran A., Burke T.W., Eifel P.J. Definitive radiotherapy for patients with isolated vaginal recurrence of endometrial carcinoma after hysterectomy. Int J Radiat Oncol Biol Physics 2003; 56(5): 1366 - 72.